|
by:
Drs. Wang Li Rong/Feng Qing Rong/Xu Xiao
Yuan/Ma Huai Liang – Department of Infection, The 1st Affiliated Hospital
of Lanzhou Medicine College, Drs. Wang Jun Zhi/Hitoshi Ito/Keishiro Shimura -
Mie University School of Medicine.
Overview
Experimental group (10 cases) of chronic hepatitis B
patients who received treatment using Agaricus Blazei grown in Japan was
studied. Inspection of items such as liver function, g-globulin and hemocyte
was carried out before and after the treatment. In the comparison with control
group, there was a significant change (P<0.005-0.001) in the values such as
connective cholic acid, serum ferritin, protein electrophoresis, coagulation
time, ALT, AST, bilirubin, leukocyte and platelets of experiment group
patients. It is conceivable that Agaricus Blazei improves the clinical symptom
of chronic hepatitis B patients, promotes the restoration of liver function and
reinforces hematopoietic cell.
(Keywords: Agaricus Blazei, Vegetable
Polysaccharides, Chronic Hepatitis B, Therapeutic Effect)
As proven by experiments and researches, Agaricus
Blazei, a fungous plant of “Shiitake” family is known to provide
reinforcement of nutrition liver and kidney. In order to examine its protective
function to hepatocytes, we conducted a treatment using Agaricus Blazei for
patients with chronic hepatitis and confirmed a satisfactory therapeutic effect
through clinical observation from May 1992 to November 1993, which we report as
follows.
Data and Method
I. Clinical Data
1. Background of the Subject Patients
The subject patients (total 20 examples) were a part
of chronic and active hepatitis B patient who were hospitalized at the
Department of Hematology, The First Affiliated Hospital of Lanzhou Medical
College during the period from May 1992 to November 1993. They were randomly
divided into an experimental group and a control group, each consisting of 10
patients. The examples comply with the diagnosis standard established at
Shanghai Hepatitis Conference held in May 1990.
2. General Data
The age of the patients of the experimental group
ranged 24 – 55 and the average was 41. The experimental group consisted of
9 males and 1 female.
The age of the patients of the control group ranged 21
– 57 and the average was 39. The control group consisted of 8 males and 2
females.
3. Expression of the Clinical Symptom
All the 20 patients were presenting the general
clinical expression of chronic hepatitis caused by virus, including fatigue,
anorexia, dark urine color, dull pain in the liver and abdominal distension.
Among them, 11 patients wore the color of liver disease on their faces, 7
patients carried spider-like nevus and liver palms, and 6 patients presented
various degrees of jaundice (serum bilirubin of one
patient was as high as 335mmol/L). All the patients
had their ALT exceeding the normal level. 6 patients were experiencing the
increase of AST or ALT/AST ratio lower than 1. Liver swellings were felt up to
0.5 – 2.0cm under ribs or 2-4cm under xiphoid. 6 patients had such
swellings and 5 patients were presenting positive ascites.
4. Diagnosis Standard
Our diagnosis complies with the clinical and
pathological standards for chronic and active hepatitis B established at
Shanghai Hepatitis Conference held in May 1990.
II. Treatment Method
1. Experimental Group (10 examples):
While they were given a standard treatment for liver
disease, the experimental group patients took Agaricus Blazei (supplied by
Japan Iwakin Co. Ltd. Laboratory) boiled in the water (daily amount of 20g,
twice a day) for 3 consecutive months. After the 3-month treatment period, the
conditions of patients were re-checked.
2. Control Group (10 examples):
The control group patients received the same standard
treatment for liver disease and they also took vitamins and energy mixture
including diuretics, digestives and antiinfectives. Albumin and complex amino
acid were also given to patients in serious condition.
III. Monitored Values
1. Changes in the Liver Functions:
ALT, AST, bilirubin, serum ferritin (ST), connective
cholic acid (CG), g-globulin and coagulation time were monitored at
pre-treatment test and post-treatment biweekly tests to see their dynamic
changes.
2. Changes in the Blood Picture:
Leukocyte and platelets were monitored before and
after treatment.
IV. Rating of Therapeutic Effect
1. The rating of the therapeutic effect established at
the Shanghai Hepatitis Conference held in May 1990 is as follows:
- Especially effective: (1) Disappearance of
subjective symptom, (2) decrease or no change in swelling and other chronic
symptom, (3) recovery of liver function ALT to normal level and improvement in
A/G ratio, and (4) negative HBVM activity replisome.
- Effective: (1) Improvement or disappearance of
subjective symptom, (2) no change in swelling and other chronic symptom, (3)
recovery of liver function ALT to normal level and no change in A/G ratio, and
(4) negative HBVM activity replisome.
- Ineffective: Any result short of the above
standards.
V. Side Effect
Patients went through rigid inspection during and
after treatment for any side effects.
VI. Statistical Processing
“T” inspection processing was applied to the
data of each item.
Result
1. Symptoms and Signs:
The symptoms of most of the experimental group
patients were improved. For example, symptoms such as abdominal distension,
fatigue and hepatodynia either disappeared or improved. Signs were also
improved to some degree. The number of patients with retraction of the liver
and spleen decreased to 5/8 and 3/6 examples respectively, and 2 examples of
ascites retraction disappeared. It was obvious that the improvement in the
clinical symptoms of the experimental group far exceeded that of the control
group.
2. After the 3-month treatment using Agaricus Blazei,
the liver function was obviously improved, and there was a remarkable change in
values including ALT, AST, bilirubin (P<0.05-0.001). It is obvious that
Agaricus Blazei has a therapeutic effect against enzyme depression and jaundice
(see Table 1).
Table 1: Influence of Agaricus Blazei to the Liver
Function of Chronic Hepatopaths (x±S) |
